SecBot SecBot
PRESS-RELEASE ·Filed Nov 12, 2026

BIIB

Biogen Inc.; Eisai Co., Ltd.
NEUTRAL
Impact 3/10
Horizonweeks Processed3d 15h ago WireGlobeNewswire
Press release · Contract
Actionable Insight • Neutral

Monitor Japan sales uptake of LEQEMBI Pen and potential reimbursement expansion; the SC formulation may broaden patient access and reduce treatment burden, but no revenue guidance was provided.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$253.40
T+0 close · Nov 12, 2026 · via day close
Latest settled
−0.69%
T+1 · $251.65
Vs SPY
+1.22%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $253.40entry
  2. T+1 · 16h ago −0.69%α +1.22% · $251.65
  3. T+5 · in 3d Pending
  4. T+20 · in 27d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Eisai and Biogen launched LEQEMBI Pen, the subcutaneous autoinjector formulation of lecanemab, in Japan following NHI Drug Price listing. This is the second country launch after the U.S., offering once-weekly self-administration to reduce clinic visit burden and healthcare resource use for Alzheimer's disease patients.

Key Facts

  • LEQEMBI Pen launched in Japan on Nov 12, 2026, after NHI Drug Price listing at 27,141 JPY per pen.
  • Japan is the second country after the U.S. to launch the subcutaneous formulation.
  • LEQEMBI Pen is an autoinjector for once-weekly self-administration (500 mg total via two pens).
  • SC formulation showed similar exposure to IV and lower injection-related reaction incidence (1.4% vs IV).
  • LEQEMBI is approved in 53 countries and regions; SC initiation approved in U.S. (July 2026) and China (Sept 2026).

Financial Impact

No financial terms disclosed; NHI Drug Price set at 27,141 JPY per pen.

revenue

Risk Factors

  • No financial impact or revenue projections stated in the release.
  • Self-administration requires careful patient selection and training; safety monitoring (MRI for ARIA) remains necessary.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
73% bullish (44 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3402340

Track record

34 reports on BIIB

Performance horizon

10 of 12 bullish or bearish reports moved the stock their way by T+60. Best: +15.73% at T+60 after the Jul 13, 2026 report. 16 of 17 went positive at some point.

Filters
  1. Nov 12, 20264d ago Press Release Neutral 3/10 Viewing Entry $253.40 Now $251.65 −0.69% settles Feb 11
  2. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $253.25 Now $251.65 −0.63% settles Feb 8
  3. Nov 9, 20267d ago Press Release Neutral 4/10 Entry $254.87 Now $251.65 −1.26% settles Feb 5
  4. Oct 28, 202619d ago Institutional Cluster Neutral 2/10 Entry $244.05 Now $251.65 +3.11% settles Jan 26
  5. Oct 28, 202619d ago 8-K Bullish 6/10 Entry $244.05 Now $251.65 +3.11% settles Jan 26
  6. Oct 19, 202628d ago Press Release Neutral 4/10 Entry $233.48 Now $251.65 +7.78% settles Jan 14
  7. Oct 12, 20265w ago ANALYST-UPGRADE Bullish 6/10 Entry $229.41 Now $251.65 +9.69% settles Jan 7
  8. Oct 2, 20266w ago Press Release Bullish 6/10 Entry $219.88 Now $251.65 +14.45% settles Dec 29
  9. Sep 17, 20268w ago Press Release Bullish 5/10 Entry $215.50 Now $251.65 +16.77% settles Dec 14
  10. Sep 3, 202610w ago Press Release Neutral 4/10 Entry $220.83 Now $251.65 +13.96% settles Dec 1
Showing 10 of 34

US Market Status

Market Closed · Opens Wed (10h 7m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 13, 2026